Table 2.

Demographics of patients with advanced HCC treated with sorafenib (N = 81)

Age, median, (range)65.2 (16–91)
Sex, male, N (%)61 (0.75)
Race, N (%)
 Asian15 (0.19)
 Non-Asian66 (0.81)
Etiology, N (%)
 HCV26 (0.32)
 HBV16 (0.20)
 Nonviral40 (0.49)
BCLC stage, N (%)
 A0 (0.00)
 B14 (0.17)
 C67 (0.83)
Extent of disease, N (%)
 Intrahepatic81 (1.00)
 Extrahepatic48 (0.59)
 Vascular involvement35 (0.43)
 AFP, ng/ML, median (range)86.8 (1.8–128876.1)
Child-Pugh, N (%)
 A78 (0.96)
 B2 (0.02)
 Unknown1 (0.01)
Prior treatment, N (%)
 Surgical resection31 (0.38)
 Regional therapy59 (0.73)
 Hepatic allograft3 (0.04)
Systemic, N (%)
 Sorafenib: first line75 (0.93)
 Sorafenib: second line6 (0.07)